4.7 Article

High Expression of microRNA-143 is Associated with Favorable Tumor Immune Microenvironment and Better Survival in Estrogen Receptor Positive Breast Cancer

Journal

Publisher

MDPI
DOI: 10.3390/ijms21093213

Keywords

microRNA-143; ER positive; breast cancer; tumor immune microenvironment; KRAS; TCGA; METABRIC; GSEA; CYT

Funding

  1. NIH [R01CA160688]
  2. National Cancer Institute (NCI) [P30CA016056]

Ask authors/readers for more resources

microRNA-143 (miR-143) is a well-known tumor suppressive microRNA that exhibits anti-tumoral function by targeting KRAS signaling pathways in various malignancies. We hypothesized that miR-143 suppresses breast cancer progression by targeting KRAS and its effector molecules. We further hypothesized that high expression of miR-143 is associated with a favorable tumor immune microenvironment of estrogen receptor (ER)-positive breast cancer patients which result in improved survival. Two major publicly available breast cancer cohorts; The Cancer Genome Atlas (TCGA) and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) were used. The miR-143 high expression group was associated with increased infiltration of anti-cancer immune cells and decreased pro-cancer immune cells, as well as enrichment of the genes relating to T helper (Th1) cells resulting in improved overall survival (OS) in ER-positive breast cancer patients. To the best of our knowledge, this is the first study to demonstrate that high expression of miR-143 in cancer cells associates with a favorable tumor immune microenvironment, upregulation of anti-cancer immune cells, and suppression of the pro-cancer immune cells, associating with better survival of the breast cancer patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biotechnology & Applied Microbiology

Extracellular sialyltransferase st6gal1 in breast tumor cell growth and invasiveness

Nitai C. Hait, Aparna Maiti, Rongrong Wu, Valerie L. Andersen, Chang-Chieh Hsu, Yun Wu, Digantkumar G. Chapla, Kazuaki Takabe, Michael E. Rusiniak, Wiam Bshara, Jianmin Zhang, Kelley W. Moremen, Joseph T. Y. Lau

Summary: Our study found that extracellular ST6GAL1 can compensate for insufficient cellular ST6GAL1, promoting cancer cell proliferation and invasiveness. Moreover, we identified novel cofactors in the exosome-like particles that amplify the action of extrinsic ST6GAL1. Overall, this study reveals the importance of ST6GAL1 in tumor pathobiology.

CANCER GENE THERAPY (2022)

Article Oncology

NR2F1, a Tumor Dormancy Marker, Is Expressed Predominantly in Cancer-Associated Fibroblasts and Is Associated with Suppressed Breast Cancer Cell Proliferation

Rongrong Wu, Arya Mariam Roy, Yoshihisa Tokumaru, Shipra Gandhi, Mariko Asaoka, Masanori Oshi, Li Yan, Takashi Ishikawa, Kazuaki Takabe

Summary: Tumor dormancy is an important mechanism for late breast cancer recurrence. This study investigates the clinical relevance of NR2F1 expression, a known biomarker for dormancy. The results show that high NR2F1 expression in breast cancer is associated with enriched metastasis and stem cell-related pathways, as well as suppressed cell proliferation. Furthermore, NR2F1 is predominantly expressed in cancer-associated fibroblasts, rather than in cancer cells.

CANCERS (2022)

Article Biochemistry & Molecular Biology

Mechano-Sensing Channel PIEZO2 Enhances Invasive Phenotype in Triple-Negative Breast Cancer

Eriko Katsuta, Kazuaki Takabe, Marija Vujcic, Philip A. Gottlieb, Tao Dai, Arnaldo Mercado-Perez, Arthur Beyder, Qingfei Wang, Mateusz Opyrchal

Summary: High expression of PIEZO2 in breast cancer, particularly in triple-negative breast cancer (TNBC), is associated with worse clinical outcomes. Activation of PIEZO2 leads to increased cell motility and invasive phenotypes, as well as the upregulation of epithelial-mesenchymal transition (EMT)-related genes.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Review Oncology

De-Escalating the Management of In Situ and Invasive Breast Cancer

Fernando A. Angarita, Robert Brumer, Matthew Castelo, Nestor F. Esnaola, Stephen B. Edge, Kazuaki Takabe

Summary: De-escalation of breast cancer treatment can reduce morbidity and improve patients' quality of life. It is considered safe if the cancer outcomes are not affected compared to more aggressive treatments. This review provides an overview of de-escalation in the treatment of ductal carcinoma in situ (DCIS), local treatment of breast cancer, and surgery after neoadjuvant systemic therapy. Advancements in understanding the natural history and biology of breast cancer, imaging techniques, and adjuvant treatments have allowed for the reduction of treatment intensity. Identifying appropriate areas for de-escalation is crucial to minimize side effects while maintaining cancer outcomes. Less aggressive treatment modalities, or even no treatment, have been reconsidered if they achieve similar oncologic results as standard therapies. Careful consideration is needed to identify which patients benefit from de-escalation, as standard therapies still offer adequate cancer outcomes. This review highlights the importance of investigating de-escalation in breast cancer treatment, with future efforts aiming to clarify the role of different treatment modalities.

CANCERS (2022)

Editorial Material Oncology

ASO Visual Abstract: Conjugated Bile Acids Accelerate Progression of Pancreatic Cancer Metastasis via S1PR2 Signaling in Cholestasis

Joy Sarkar, Hiroaki Aoki, Rongrong Wu, Masayo Aoki, Phillip Hylemon, Huiping Zhou, Kazuaki Takabe

ANNALS OF SURGICAL ONCOLOGY (2023)

Article Oncology

Conjugated Bile Acids Accelerate Progression of Pancreatic Cancer Metastasis via S1PR2 Signaling in Cholestasis

Joy Sarkar, Hiroaki Aoki, Rongrong Wu, Masayo Aoki, Phillip Hylemon, Huiping Zhou, Kazuaki Takabe

Summary: This study found that conjugated bile acids (CBAs) accumulated in cholestasis accelerate the growth of pancreatic cancer (PC) through S1PR2, indicating S1PR2 as a potential therapeutic target for metastatic pancreatic cancer.

ANNALS OF SURGICAL ONCOLOGY (2023)

Review Cell Biology

Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer

Irene Yu, Anthony Dakwar, Kazuaki Takabe

Summary: Immunotherapy has shown significant progress in the treatment of colorectal cancer (CRC) in the past decade. Immune checkpoint inhibitors have been particularly effective in improving patient outcomes in a specific subset of CRC. The efficacy and timing of immunotherapy for other subsets of CRC have gained attention, and this review discusses the latest advances and future directions for three main classes of immunotherapy for CRC: immune checkpoint inhibitors, adoptive cell transfer therapy, and tumor vaccines.

CELLS (2023)

Article Biochemistry & Molecular Biology

Lysophosphatidic Acid Receptor Signaling in the Human Breast Cancer Tumor Microenvironment Elicits Receptor-Dependent Effects on Tumor Progression

Matthew G. K. Benesch, Rongrong Wu, Xiaoyun Tang, David N. Brindley, Takashi Ishikawa, Kazuaki Takabe

Summary: Lysophosphatidic acid receptors (LPARs) play a role in promoting tumorigenesis and therapy resistance in various cancer subtypes. Our study found that increased expression of LPAR1, LPAR4, and LPAR6 correlated with a less aggressive phenotype, while high expression of LPAR2 was associated with increased tumor grade, mutational burden, and decreased survival. Different LPARs were also expressed in different cell types, suggesting potential compensatory signaling in LPAR inhibitor therapy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Surgery

E2F target score is associated with cell proliferation and survival of patients with hepatocellular carcinoma

Kohei Chida, Masanori Oshi, Arya Mariam Roy, Takafumi Yachi, Masaki Nara, Kyogo Yamada, Osamu Matsuura, Tadashi Hashizume, Itaru Endo, Kazuaki Takabe

Summary: This study found that the E2F target score, reflecting the activity of E2F target genes, is associated with the aggressiveness and prognosis of hepatocellular carcinoma. High E2F target score is associated with tumor grade, size, staging, proliferation score, MKI67 expression, as well as reduced abundance of hepatocytes and stromal cells. It is also associated with higher intratumoral genomic heterogeneity, homologous recombination deficiency, and progression of hepatocellular carcinoma.

SURGERY (2023)

Article Oncology

Decreased Lipid Phosphate Phosphatase 1/3 and Increased Lipid Phosphate Phosphatase 2 Expression in the Human Breast Cancer Tumor Microenvironment Promotes Tumor Progression and Immune System Evasion

Matthew G. K. Benesch, Rongrong Wu, Xiaoyun Tang, David N. Brindley, Takashi Ishikawa, Kazuaki Takabe

Summary: The lipid phosphate phosphatases (LPPs) are enzymes that regulate signaling in cells. Imbalance of LPP expression levels, with decreased LPP1/3 and increased LPP2, is associated with worse tumor biology, immune system evasion, and decreased survival in breast cancers. Most tumor LPP1/3 is produced by the stroma and LPP2 by cancer cells. Restoring the balance in LPP expression levels, particularly through LPP2 inhibition, could provide adjunct therapies for breast cancer patients.

CANCERS (2023)

Article Oncology

GALNT1 Expression Is Associated with Angiogenesis and Is a Prognostic Biomarker for Breast Cancer in Adolescents and Young Adults (AYA)

Masanori Oshi, Danya Ziazadeh, Rongrong Wu, Kohei Chida, Akimitsu Yamada, Shinya Yamamoto, Kazutaka Narui, Li Yan, Takashi Ishikawa, Itaru Endo, Kazuaki Takabe

Summary: In this study, we identified a gene GALNT1 that is associated with poor prognosis in breast cancer patients specifically in the adolescent and young adult population. This finding provides new insights for the treatment of young patients.

CANCERS (2023)

Article Oncology

Conjugated Bile Acids Accelerate Progression of Pancreatic Cancer Metastasis via S1PR2 Signaling in Cholestasis

Joy Sarkar, Hiroaki Aoki, Rongrong Wu, Masayo Aoki, Phillip Hylemon, Huiping Zhou, Kazuaki Takabe

Summary: This study found that conjugated bile acids (CBAs) accelerate the growth of S1PR2 predominant pancreatic cancer, suggesting that S1PR2 may be a potential therapeutic target for metastatic pancreatic cancer.

ANNALS OF SURGICAL ONCOLOGY (2023)

Meeting Abstract Oncology

Bidirectional signaling between mitochondria and the nucleus dictates epigenetic rewiring to drive tumorigenesis.

Abhisha Sawant Dessai, Nadya Elhalawany, Eriko Katsuta, Christian Prechtl, Spencer Rosario, Bert W. O'Malley, Xiang H. Zhang, Subhamoy Dasgupta

CANCER RESEARCH (2022)

Article Oncology

Low HECTD1 mRNA expression is associated with poor prognosis and may be correlated with increased mitochondrial respiratory function in breast cancer

Yasuaki Uemoto, Eriko Katsuta, Naoto Kondo, Yumi Wanifuchi-Endo, Takashi Fujita, Tomoko Asano, Tomoka Hisada, Mitsuo Terada, Akiko Kato, Katsuhiro Okuda, Hiroshi Sugiura, Masayuki Komura, Hiroyuki Kato, Satoshi Osaga, Satoru Takahashi, Tatsuya Toyama

Summary: HECTD1 mRNA expression is significantly decreased in breast cancer tissues and is associated with aggressive tumor characteristics and poor prognosis in breast cancer patients. HECTD1 expression is inversely correlated with genes involved in mitochondrial cellular respiratory function in breast cancer.

AMERICAN JOURNAL OF CANCER RESEARCH (2022)

Article Oncology

H2AX mRNA expression reflects DNA repair, cell proliferation, metastasis, and worse survival in breast cancer

Eriko Katsuta, Abhisha Sawant Dessai, John M. L. Ebos, Li Yan, Toru Ouchi, Kazuaki Takabe

Summary: The phosphorylated histone variant, gamma-H2AX, plays a key role in breast cancer, and its high expression is associated with increased DNA repair, cell proliferation, metastasis, and worse survival.

AMERICAN JOURNAL OF CANCER RESEARCH (2022)

No Data Available